Opioids like morphine are widely used in medical practice due to their powerful pain-relieving effects. However, they carry the risk of serious adverse effects such as respiratory depression and drug dependence. For this reason, Japan has strict regulations in place to ensure that these medications are prescribed only by authorized physicians.
In the United States, however, the opioid OxyContin was once prescribed frequently triggering a surge in the misuse of synthetic opioids such as fentanyl. As a result, the number of deaths caused by opioid overdose surpassed 80,000 in 2023, escalating into a national public health crisis now referred to as the “opioid crisis.”
Opioids may soon have a rival, however. A team of researchers at Kyoto University has recently discovered a novel analgesic, or pain reliever, which exerts its effect through an entirely different mechanism. Clinical development of their drug ADRIANA is currently underway as part of an international collaborative effort.
“If successfully commercialized, ADRIANA would offer a new pain management option that does not rely on opioids, contributing significantly to the reduction of opioid use in clinical settings,” says corresponding author Masatoshi Hagiwara, a specially-appointed professor at Kyoto University.
The research team was first inspired by substances that mimic noradrenaline, which is released in life-threatening situations andactivates α2A-adrenoceptors to suppress pain. However, these pose a high risk of cardiovascular instability. After observing noradrenaline levels and α2B-adrenoceptors, the team hypothesized that selectively blocking α2B-adrenoceptors could elevate noradrenaline levels, leading to activation of α2A-adrenoceptors and resulting in pain relief without causing cardiovascular instability.
To identify selective inhibitors of α2B-adrenoceptors and measure the activity of individual α2-adrenoceptor subtypes, the researchers employed a novel technology known as the TGFα shedding assay and conducted compound screening leading to their discovery of the world’s first selective α2B-adrenoceptor antagonist.
After success in administering the compound to mice and conducting non-clinical studies to assess its safety, physician-led clinical trials were conducted at Kyoto University Hospital. Both the Phase I trial in healthy volunteers and the Phase II trial in patients with postoperative pain following lung cancer surgery yielded highly promising results.
Building on these outcomes, preparations are now underway for a large-scale Phase II clinical trial in the United States, in collaboration with BTB Therapeutics, Inc, a Kyoto University-originated venture company.
As Japan’s first non-opioid analgesic, ADRIANA has the potential not only to relieve severe pain for patients worldwide but could also play a meaningful role in addressing the opioid crisis — a pressing social issue in the United States — and thus contribute to international public health efforts.
“We aim to evaluate the analgesic effects of ADRIANA across various types of pain and ultimately make this treatment accessible to a broader population of patients suffering from chronic pain,” says Hagiwara.
Researchers have tested a new cancer drug in pet cats with head and neck squamous cell carcinoma – a disease notoriously hard to treat. The trial showed the therapy controlled cancer in 35 percent of cats with minimal side effects – and it could help to treat humans too.
A new study, published in Cancer Cell, has found that 35 percent of cats that received a new class of targeted therapy to treat head and neck squamous cell carcinoma (HNSCC) had the disease controlled with minimal side effects. Researchers believe the drug could also be effective for humans with HNSCC.
“There are two major findings from this study,” says senior author Daniel Johnson of the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center. “It showed us that it’s possible to target a transcription factor that drives oncogenesis, which is something that has been notoriously difficult in the past. Also, it demonstrated that pets with cancer can be a good representation of human disease and that clinical trials in pets may yield more reliable results than tests in mouse models.”
The drug, initially designed for human head and neck cancers, is the first to target the transcription factor STAT3, which is present in a variety of both solid and liquid tumours – including a majority of HNSCC cases.
Of the 20 cats enrolled in the trial, 7 exhibited either a partial response or stable disease during the study period. Among those that responded, the average survival post-treatment was 161 days. Other than mild anaemia, none of the cats developed side effects linked to the treatment.
Of the 20 cats enrolled in the trial, 7 exhibited either a partial response or stable disease during the study period.
Analysis of tumours and blood samples demonstrated that the drug worked in two ways: it blocked STAT3 activity and raised levels of PD-1– a protein linked to an immune response against cancer.
“This study is a great example of how we can think more carefully about spending our very limited resources on studies in lab mice that are not even the best models of human cancers,” Grandis says. “By partnering with veterinary oncologists and doing clinical trials in companion animals, we can learn an enormous amount about how these drugs work while also helping people’s pets. None of the cats in these trials were harmed, and many of them benefited.”
The researchers note that studies in pets may be a superior model for predicting how drugs will behave in humans compared with traditional mouse studies. They are working with a small biotech company to advance the new compound in trials for both pets and humans.
“These animals breathe the same air that we breathe and are exposed to all the things we’re exposed to,” says Johnson. “Their tumours are much more heterogeneous, which makes them a better mimic of human disease.”
When Sakamoto made it clear the upcoming season would be her farewell tour, there was no drama or tears. It was filled with her trademark hearty laughs and ear-to-ear big smiles.
While the official announcement was made only three months ago, Sakamoto knew not long after Beijing 2022 that the Milano Cortina campaign would be it for her.
The Kobe native won a singles bronze at the Beijing Games, becoming the fourth female figure skater from Japan to set foot on the Olympic podium.
She also helped her country to its first medal in the team event, producing a then-personal best free skate as Japan took home silver.
What more could Sakamoto achieve, really? The only thing missing from her impressive trophy cabinet most skaters would kill for was an Olympic gold medal, and those can be hard to come by.
But it was the journey. The camaraderie. The honour of representing Japan in a sport which the country is mad about.
That is what brought Sakamoto back for one, last dance.
“Being honest, I was ready to quit anytime because I won a medal both in the team event and as an individual in Beijing,” said Sakamoto, who wants to go into coaching after retiring and groom future Sakamoto Kaoris in her hometown of Kobe where she continues to be based.
“But I really wanted to experience the Olympics one more time, and I knew there wouldn’t be another opportunity beyond (Milano Cortina).
“So I was determined then and there to give it everything I have for another four years and now the clock is really starting to tick.”
WhatsApp is preparing a major update to its Status feature, borrowing a concept that will be instantly familiar to Instagram users. The messaging platform, owned by Meta, is reportedly developing a ‘Close Friends’ option for Status updates — a move that could make sharing content on the app more personal and private than ever before.
For users less familiar with the feature, WhatsApp Status operates much like Instagram Stories. It allows people to post photos, videos or text updates that automatically vanish after 24 hours. While Status may not enjoy the same level of popularity in the United States, it has become a global success story. According to Meta, more than 1.5 billion people worldwide use WhatsApp Status every day.
At present, WhatsApp provides three privacy settings for Status updates. The first, My Contacts, shares posts with everyone in a user’s address book. The second, My Contacts Except…, allows users to exclude specific individuals. The third, Only Share With…, enables the selection of a smaller group of people.
Although the Only Share With… setting already functions as an informal version of ‘Close Friends’, the new feature is expected to be far more seamless. As reported by WABetaInfo, which identified the change in WhatsApp’s TestFlight beta release, the platform will soon allow users to create a dedicated Close Friends list directly from the privacy settings.
Once a list has been set up, users will be able to decide each time they post a Status update whether to share it with their full contact list or restrict it to their chosen inner circle. In a nod to Instagram’s design, Close Friends updates will also be visually distinct. A special-coloured ring will highlight these posts, signalling to recipients that they are viewing something more personal.
Equally significant is the privacy aspect. As with Instagram, WhatsApp’s Close Friends list will remain discreet. No notifications will be sent when someone is added to or removed from the list.
The addition is expected to make WhatsApp Status more attractive to those who prefer to share updates casually without broadcasting to their entire contact network. It also reflects Meta’s broader strategy of aligning features across its family of apps, ensuring that users enjoy similar tools whether they are using WhatsApp or Instagram.
“Monza has got a very particular DNA,” explains Deputy Technical Director Simone Resta, who in 2025 is preparing for his first Italian Grand Prix since joining our Brackley family at the end of last season.
“Monza has always been the image of speed, the light cars, and the little wings.
“Then there are the surroundings, inside the park under the trees. It is all so historical and unique. The original Parabolica, around the banking, is such a great corner, it is so impressive when you see it in real life.
“The level of risk those drivers were taking in the past was so impressive. They really were pioneers.”
Simone’s earliest F1 memories do not actually involve Monza. Instead, it was the sights and sounds of Imola – 275km south-east away – that first drew the Italian to Formula 1.
“I could hear the noise of the cars from my house, and that made me more passionate about this world.
“At the start of the early 80s I would go to Rivazza with my dad to watch the cars go by. It led me to university and that all started my journey to the sport.
“Both Monza and Imola meant a lot to me. They meant passion, they meant being closer to the event, so they definitely helped in building and cementing this love I have for the sport.”
Like so many who have plied their trade in F1 for the majority of their working life, some of the most vivid memories of Simone’s time at Monza come from those full circle family moments.
“In the first few years I remember walking with my girlfriend – who is now my wife – to the track through the trees, having parked a long way away.
“There were lots of places to eat, drink, and dance – it was one big show and proves that the event can attract such a wide audience.
“Years later, we went back with our two children – and the level of noise was very high when the cars came by at full throttle along the straight.
“My daughter and son were very young, so we had to put earplugs in their ears, but even with those in they were still crying because of the noise!”
Britain’s long-term borrowing costs have hit their highest level in 27 years, intensifying the pressure on chancellor Rachel Reeves before the autumn budget.
The yield, or interest rate, on 30-year UK government debt hit 5.680% on Tuesday morning. That is its highest level since 1998, indicating that it will cost the UK more to borrow from the markets, above the previous 27-year high of 5.649% set in April.
Yields, which rise when a bond’s price falls, are a measure of the interest rate which investors demand when lending to a government or company.
The UK 30-year bond yield has been rising steadily over the last year, amid a wider global sell-off in long-term government bonds. Analysts have blamed that sell-off on rising inflationary expectations – meaning lenders seek a higher rate of return.
While bond prices fell on Tuesday, traders piled in to precious metals in a flight to safety. This pushed the gold price up to a new record high of $3,508 (£2,607) an ounce on Tuesday, while silver rose over $40 an ounce for the first time since 2011.
Anxiety over fiscal sustainability are another factor, with Donald Trump’s recent tax cuts and spending bill expected to add trillions of dollars to the US national debt.
In the UK, opposition to proposed welfare cuts have highlighted the challenge in cutting government spending.
Rising borrowing costs are a blow to the UK chancellor, as they eat into the limited fiscal headroom available to the Treasury. It may force Reeves to consider tax rises, or spending cuts, to ensure she still hits her fiscal rule to have debt falling in five years’ time.
The rise in borrowing costs came as the City digested Keir Starmer’s decision to reshuffle his Downing Street organisation on Monday, including putting Darren Jones, the chief secretary to the Treasury, in charge of day-to-day delivery of the prime minister’s priorities.
“The immediate market reaction is not exactly a vote of confidence on these moves,” said Simon French, the chief economist and head of research at the investment bank Panmure Liberum.
after newsletter promotion
“Markets [are] seeing it as a signal of more gilt issuance/inflation to come,” French said.
Rob Morgan, the chief investment analyst at Charles Stanley, said: “Bond market trends are adding to the pressure on government finances. Escalating global inflation concerns and fewer price insensitive buyers such as pension funds have helped pushed up yields on UK government bonds, adding to the question marks around the UK’s fiscal credibility.
“At this sort of level any misstep such as a clumsy handling of previously ‘iron clad’” fiscal rules could be severely punished by markets, risking a ‘doom loop’ of ever higher borrowing costs, greater economic pain, and lower tax revenue. The chancellor needs to keep bond markets onside as a matter of priority as waning investor confidence from this point could be hugely damaging.”
Platypus – Greek for ‘flat-footed’ – may sound a derogatory name, but that was the least of the problems encountered by these small mole-like creatures from Australia. When the British Museum received its first specimen in 1799 the curator, George Shaw, was convinced that it must be a fake and attacked it with a pair of scissors in a failed attempt to detach the beak. Even when persuaded the animal was genuine he remained baffled, expostulating that of ‘all the Mammalia yet known it seems the most extra-ordinary in its conformation’ – and despite that reference to a mammal, the scientific label he devised suggests he thought it was a bird: Platypus anatus (anatus is Latin for ‘duck’).
Three years later in Germany, renowned anatomist Johann Blumenbach reached a different conclusion. When a skin arrived from John Hunter, governor of New South Wales, Blumenbach denigrated it as Ornithorhynchus paradoxus, or ‘paradoxical bird-snout’. Debates about its identity proliferated as zoologists tried to accommodate this Antipodean discovery within an outdated European classification system. Eventually they settled on a permanent, if somewhat unsatisfactory, name. Two conventions came into play: platypus had to be jettisoned because it had already been adopted for some recently discovered beetles; and paradoxus also had to go, because taxonomic courtesy entailed standing by the initial nomenclature. The cumbersome compromise was Ornithorhynchus anatinus, which at least side-stepped the problem of remembering the appropriate plural of platypus (platypuses, not platypi).
For decades, question marks hovered over the nature of the beast. Newcastle engraver Thomas Bewick is best known as an ornithologist, but he neatly summed up the quandary, remarking in 1800 that it was ‘an animal sui generis; it appears to possess a three-fold nature, that of a fish, a bird, and a quadruped, and is related to nothing that we have hitherto seen’. Fascinated yet puzzled, 19th-century scientists competed to unravel the mystery. Charles Darwin was thrilled to be included in a successful hunting expedition, although he did boast rather chillingly that ‘I consider it a great feat to be in at the death of so wonderful an animal’.
Traditional classification systems had been bursting at the seams ever since new species began arriving in Europe from the Americas. Under the old Aristotelian scheme, terrestrial life had been arranged in a single hierarchical chain that lay stretched out between inanimate minerals at the bottom and supra-human angels at the top. At the lower end of this ladder lay plants, followed in ascending order by insects, fish, and birds before reaching the quadrupeds; above them, the upper rungs were occupied by primates and, finally, human beings.
That neat simplicity was being challenged long before the egg-laying, duck-billed, warm-blooded enigma appeared on the scene. Mammals, generally the most emotionally and economically significant animals for people, were often differentiated as ‘viviparous quadrupeds’, characterised not only by moving around on four feet, but also by giving birth to live offspring and dwelling on land. That solution provided a sensible way of distinguishing them from four-legged lizards and salamanders that lay eggs – but what about whales and walruses with no feet, or bats that have two wings and only two feet? For hundreds of years, several anomalies were included as if they were honorary quadrupeds.
Whenever explorers triumphantly brought home exotic treasures from distant lands, they somehow had to be absorbed within this imperfect system. In the first half of the 18th century the number of species doubled from 150 to 300 – and by the end of the 19th century more than 1,000 new genera (each potentially including multiple species) were turning up each year. As a writer in Nature put it, this was ‘a simply appalling number’. Marsupials – opossums from South America and kangaroos from Australia – presented particular problems. If possessing a pouch was the main defining criterion, perhaps they could be squeezed in between bears and weasels? On the other hand, if feeding habits were more important, then opossums should be grouped with carnivores and kangaroos with ruminants.
The term quadruped gradually faded away as mammal was perceived to be a more useful concept. But that made it even more difficult to determine the status of the platypus, which was reputed to lay eggs but also to suckle its young. One defiant protagonist declared himself undefeated:
from the want of mammae, and from the structure of the sexual organs, the naturalist surely cannot, with any degree of propriety, arrange this animal with the Mammalia; and very few will be hardy enough … to think of arranging it with Birds or Fishes. The only possible class that remains, is the Amphibia.
But amphibians are cold-blooded, so that solution hardly seemed viable.
Other zoologists pondered the question more creatively, even inventing new groups. French evolutionist Jean-Baptiste Lamarck proposed that platypuses should join echidnas (spiny anteaters) in a non-mammalian class, ‘Prototheria’, while Shaw of the British Museum suggested lumping them together with anteaters and sloths as toothless animals. The debates straggled on for decades. Although plenty of self-styled experts relished the opportunity to make grand pronouncements, they were hampered by a shortage of reliable information. Restricted to examining dead samples in museums and laboratories, European zoologists were in the wrong place for settling the vital question: was it really true that this furry paradox laid eggs?
The true experts remained mostly invisible, unheeded and unnamed: the Aboriginal Australians had been interacting with indigenous fauna long before the first Europeans arrived to declare that they owned the land and that they knew best. Some curious visitors took advantage of local skills and traditions, although results were not guaranteed: ‘I was doomed not to see a living platypus or even a Kangaroo’, lamented Henry Nottidge Moseley, a naturalist on HMS Challenger: ‘I saw only the footprint of the Platypus (like those of a duck).’
Success demanded perseverance. To obtain his specimen for Blumenbach, Hunter had waited for an hour while an experienced fisherman sat patiently by a river, watching his prey surface periodically to take a breath; when he judged the moment was right, he suddenly lunged forward and pierced it with his short wooden spear. Like many other long-term Australians, this anonymous angler was well versed in platypus habits, but many Europeans refused to accept their accounts of eggs as proof, instead insisting on the necessity of scientific training.
There were three major schools of thought, driven by personal and national rivalries as much as by scientific logic. Some French and German biologists chose the easy option of maintaining that platypuses bear live young just like more familiar mammals, while others decreed that they should be placed in a separate category because they laid eggs. Britain’s most vocal representative was the vituperative Richard Owen, who insisted that the eggs were very large but stayed inside the mother’s body. Operating at long-distance from London, he sent out ruthless instructions for resolving the dispute: every week during the breeding season, a specially convened shooting party should kill a female platypus and investigate the state of any eggs. Luckily, the curator of the Australian Museum called a halt to this massacre before the animals fell extinct.
Eager to gratify European curiosity, collectors despatched eggs from other creatures – tortoises, snakes, lizards – and some gullible scientists duly published accounts in scholarly journals. It took 80 years for the colonial invaders to confirm that platypuses do indeed lay eggs, even though that had long been common knowledge among local people. As a Sydney newspaper explained, for evidence to be accepted it must be ‘examined and reported on by scientists in whom all the world has faith’.
Eventually, the matter was settled in under six months of field work by William Caldwell, a recent Cambridge graduate who solicited funds for a research project with the aim of finding platypus eggs. Where others had failed, he succeeded by recruiting over 100 Aboriginal assistants to join him in his search. Spending hours every day in the water, he was soon able to report that: ‘I shot an Ornithorynchus whose first egg had been laid; her second egg was in a partially dilated os uteri [cervical canal]. This egg … was at a stage equal to a 36-hour chick.’
In his quest for scientific truth, Caldwell slaughtered 70 females from a single pond in just three months. Numbers plummeted towards the end of the 19th century. In 1912 this unique species – the sole living representative of its family – became legally protected. Once the scientific controversies had been resolved, tempers cooled, and the poet Ogden Nash could indulge in a more whimsical view:
I like the duck-billed platypus
Because it is anomalous.
I like the way it raises its family,
Partly birdly, partly mammaly.
I like its independent attitude.
Let no one call it a duck-billed platitude.
Patricia Fara is an Emeritus Fellow of Clare College, Cambridge.
We recently compiled a list of the 10 High Growth Pharma Stocks That Are Profitable in 2025. Zoetis Inc. is one of them.
Zoetis Inc. (NYSE:ZTS), a New Jersey–based global leader in animal health, continues to strengthen its position in the industry with medicines and vaccines for both companion animals and livestock. The company is particularly recognized for its innovations in parasiticides, dermatology, and vaccines that enhance animal well-being.
In its second-quarter 2025 earnings report, Zoetis Inc. (NYSE:ZTS) delivered stronger-than-expected results, posting $2.5 billion in revenue, an 8% increase driven by both volume and price growth. Building on this momentum, the company raised its full-year revenue outlook to between $9.45 billion and $9.60 billion, underscoring confidence in sustained demand across key markets and reinforcing its standing among high growth stocks in the animal health sector.
Growth was fueled largely by the continued success of Simparica Trio, a leading flea, tick, and heartworm treatment for pets, as well as strong performance in dermatology products, including Apoquel, Solens, and Cytopoint. The livestock segment also showed signs of recovery, though it faced competitive pressures and supply challenges.
CEO Kristin Peck emphasized Zoetis Inc. (NYSE:ZTS)’ resilience amid macroeconomic headwinds, crediting disciplined execution and a sharp focus on innovation. She also highlighted the corporation’s opportunities for expansion, citing recent product approvals and label extensions across global markets such as Japan, Australia, Brazil, and the EU.
While we acknowledge the potential of ZTS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure. None.
With the opening of this new office, Cadeler will be even better positioned to pursue and deliver offshore wind projects across the many growing markets in the region – from Taiwan’s well-developed offshore wind sector to emerging hubs such as Vietnam, the Philippines, South Korea, Australia, and beyond.
Following its merger with Seajacks/Eneti in 2023, Cadeler has built on a solid regional foundation in Taiwan. The company has been a pioneer in Taiwan’s offshore wind market, establishing a strong track record including Taiwan’s first commercial scale offshore wind farm, the Formosa 1.
Today, Cadeler has two vessels actively operating in Taiwanese waters, with Wind Maker installing 14 MW turbines at Ørsted’s Greater Changhua 2b & 4 Offshore Wind Farm and Wind Zaratan active on a long-term service agreement with Vestas.
Looking ahead, Cadeler’s vessels have secured a regional pipeline that runs through the end of the decade. In 2027, Wind Maker and her crew are contracted to install turbines at Copenhagen Infrastructure Partners’ Fengmiao 1 project. And in 2028, Cadeler will install Siemens Gamesa 14 MW turbines at the Formosa 4 Offshore Wind Farm in Taiwan developed by Synera Renewable Energy (SRE).
The Asia-Pacific region is a key growth market for offshore wind. Taiwan continues to lead, with several offshore wind farms already in operation and more in development. South Korea and Japan are raising their ambitions, and new opportunities lie ahead in deep-water markets such as Australia. Vietnam has reaffirmed its offshore wind targets, the Philippines has just launched its first auction, and Singapore is positioning itself as a key importer of renewable energy.
“Cadeler’s new Taipei office becomes the hub for expanding our regional footprint – supporting local teams, anchoring client relationships, and coordinating cross-border opportunities as we build momentum for the clean energy future across Asia-Pacific,” says Mikkel Gleerup, Cadeler CEO.
The new Taipei office is fully aligned with Cadeler’s European office design and branding and will accommodate at least twice as many people, with room for further growth. It offers excellent views of the city skyline and sits right next to the newly opened Taipei Dome – a 40,000-capacity indoor stadium that hosts baseball games and international concerts.
“The new Taipei office is more than a workspace – it reflects our confidence in the region’s potential across diverse markets. With two vessels already active in Taiwan and a strong pipeline ahead, the new Taipei office gives us the space and strength to meet growing demand,” comments Tony Lu, APAC Manager at Cadeler.
***